Related Experiment Videos
Gender difference in ranolazine pharmacokinetics in rats
1Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, People's Republic of China.
European Journal of Drug Metabolism and Pharmacokinetics
|July 25, 2003
Summary
Gender significantly impacts ranolazine (RAN) pharmacokinetics in rats. Female rats exhibit higher plasma concentrations, drug exposure, and tissue accumulation of RAN compared to males, indicating a notable sex-based difference.
Area of Science:
- Pharmacology
- Toxicology
- Drug Metabolism
Background:
- Ranolazine (RAN) is an antianginal medication.
- Understanding its pharmacokinetic profile is crucial for safe and effective dosing.
- Potential gender-based differences in drug disposition warrant investigation.
Purpose of the Study:
- To investigate the pharmacokinetic differences of ranolazine (RAN) between female and male rats.
- To quantify plasma concentrations, tissue distribution, and excretion of RAN in relation to gender.
Main Methods:
- Oral administration of RAN at doses of 12.5, 25, and 50 mg/kg to rats.
- Quantification of RAN plasma concentrations using analytical methods.
- Analysis of RAN concentrations in tissues, urine, and bile.
Main Results:
- Female rats showed significantly higher plasma RAN concentrations and overall drug exposure (Cmax, AUC) compared to male rats.
- Male rats had shorter elimination half-lives (T1/2) and mean residence times (MRT).
- Higher RAN recoveries were observed in urine and bile, along with greater tissue concentrations, in female rats.
Conclusions:
- Marked gender differences exist in the pharmacokinetics of ranolazine in rats.
- Females exhibit higher RAN exposure and accumulation, suggesting potential sex-specific dosing considerations.